Received: 18 March 2021
Accepted: 2 November 2021
First Online: 10 November 2021
: This study analysis was approved by the Heartland Institutional Review Board, USA. All participants gave informed consent to have the anonymized transcripts shared, analyzed, and published with the purpose of helping other patients, healthcare providers, caregivers, or others who have a role in the treatment of people with HBV understand their experiences, perceptions, and desires related to HBV.
: All authors listed within this manuscript were involved in the development, design, writing, and analysis and give their consent for publication.
: CF served on a community advisory board for Gilead; SK is a GSK employee and stockholder; CC represents the Hepatitis B Foundation on community advisory boards for GSK and Gilead; the Hepatitis B Foundation receives unrestricted educational grants from GSK, Gilead, Janssen, BMS, Arbutus and Antios.